SEC Comment Letter for BioPharmX Corp (CIK 0001504167) — Jul 6, 2022
BioPharmX Corp (CIK 0001504167)
Date: July 6, 2022 · CIK: 0001504167 · Accession: 0000000000-22-007158
AI Filing Summary & Sentiment
File numbers found in text: 333-265974
Letter
United States securities and exchange commission logo July 6, 2022 Joseph Lucchese Chief Financial Officer Timber Pharmaceuticals, Inc. 110 Allen Road, Suite 401 Basking Ridge, New Jersey 07920 Re:Timber Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 1, 2022 File No. 333-265974 Dear Mr. Lucchese: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alan Wovsaniker, Esq.
Show Raw Text
United States securities and exchange commission logo
July 6, 2022
Joseph Lucchese
Chief Financial Officer
Timber Pharmaceuticals, Inc.
110 Allen Road, Suite 401
Basking Ridge, New Jersey 07920
Re:Timber Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed July 1, 2022
File No. 333-265974
Dear Mr. Lucchese:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alan Wovsaniker, Esq.